This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sharpe, D A. Articles by Kay, P H Search for Related Content PubMed PubMed Citation Articles by Sharpe, D A. Articles by Kay, P H Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Coronary Artery Bypass Surgery Hazardous Substances DB DOPAMINE INDOCYANINE GREEN Social Bookmarking                         What's this?

Enhancing liver blood flow after cardiopulmonary bypass: the effects of dopamine and dopexamine

Department of Cardiothoracic Surgery, The Yorkshire Heart Centre, The General Infirmary at Leeds, Great George Street, Leeds

I M Mitchel

Department of Cardiothoracic Surgery, The Yorkshire Heart Centre, The General Infirmary at Leeds, Great George Street, Leeds

E A Kay

Department of Pharmacy, The Yorkshire Heart Centre, The General Infirmary at Leeds, Great George Street, Leeds

J P McGoldrick

Department of Cardiothoracic Surgery, The Yorkshire Heart Centre, The General Infirmary at Leeds, Great George Street, Leeds

C M Munsch

Department of Cardiothoracic Surgery, The Yorkshire Heart Centre, The General Infirmary at Leeds, Great George Street, Leeds

P H Kay

Department of Cardiothoracic Surgery, The Yorkshire Heart Centre, The General Infirmary at Leeds, Great George Street, Leeds

Liver blood flow is reduced after cardiopulmonary bypass (CPB) and both dopamine and dopexamine are used to overcome this. This study compares the effects of these agents on liver blood flow. Thirty patients undergoing elective coronary artery bypass graft surgery were randomized into three groups (n = 10 per group). Six hours after surgery baseline liver blood flow was determined by the percentage disappearance rate of indocyanine green measured by dichromatic auricular densitometery. Patients then received infusions of either: (1) placebo (dextrose 5%); (2) dopamine (4 µg/kg/min); (3) dopexamine (1 µg/kg/min increasing to 2 µg/kg/min). One hour after infusion, liver blood flow measurements were repeated. In the dopexamine group the infusion was increased and the measurements repeated another hour later.

We found that patient-specific variables and operative details were similar for all groups. Postoperative cardiac index and heart rate were increased significantly by dopamine (cardiac index 2.82 ± 0.46 l/m/m² vs 3.28 ± 0.67 l/m/m²: p < 0.001 and heart rate 87.5 ± 13.2 vs 96 ± 16: p < 0.05) and dopexamine at 2 µg/kg/min (cardiac index 2.71 ± 0.53 l/m/m² vs 3.45 ± 0.67 l/m/m²: p < 0.05 and heart rate 89.0 ± 18.9 vs 107.4 ± 13.6: p < 0.001) compared to placebo (cardiac index 2.97 ± 0.8 l/m/m² vs 3.18 ± 0.9 l/m/m²: p > 0.05 and heart rate 77.2 ± 7.4 vs 77.3 ± 8: p > 0.05) despite similar atrial and systemic arterial pressures. The disappearance rate of indocyanine green was not altered during infusion of placebo group (9.0 ± 3.2%/min vs 7.9 ± 3.0%/min: p > 0.05) or dopexamine at 1 µg/kg/min (9.7 ± 3.1%/min vs 11.2 ± 4.1%/min: p > 0.05). The disappearance rate was increased with dopamine (6.7 ± 3.7%/min vs 11.8 ± 3.0%/min: p < 0.05) and dopexamine 2 µg/kg/min (9.7 ± 3.1%/min vs 13.5 ± 3.2%/min: p < 0.05). This indicates a 76% increase in liver blood flow with dopamine and a 38% increase with dopexamine.

We conclude that dopamine 4 µg/kg/min and dopexamine 2 µg/kg/min increase liver blood flow, although this may, in part, be related to an increase in cardiac output. Dopexamine shows no advantage over dopamine in enhancing liver blood flow after CPB.

Perfusion, Vol. 14, No. 1, 29-36 (1999)
DOI: 10.1177/026765919901400105


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. K. P. Adluri, A. V. Singh, J. Skoyles, A. Robins, A. Hitch, M. Baker, and I. M. Mitchell The effect of fenoldopam and dopexamine on hepatic blood flow and hepatic function following coronary artery bypass grafting with hypothermic cardiopulmonary bypass Eur. J. Cardiothorac. Surg., June 1, 2009; 35(6): 988 - 994. [Abstract] [Full Text] [PDF]

				C. Prasser, M. Abbady, C. Keyl, A. Liebold, M. Tenderich, A. Philipp, and C. Wiesenack Effect of a miniaturized extracorporeal circulation (MECCTMSystem) on liver function Perfusion, July 1, 2007; 22(4): 245 - 250. [Abstract] [PDF]

				J. O. Friedrich, N. Adhikari, M. S. Herridge, and J. Beyene Meta-Analysis: Low-Dose Dopamine Increases Urine Output but Does Not Prevent Renal Dysfunction or Death Ann Intern Med, April 5, 2005; 142(7): 510 - 524. [Abstract] [Full Text] [PDF]

				M. C. Renton and C. P. Snowden Dopexamine and its role in the protection of hepatosplanchnic and renal perfusion in high-risk surgical and critically ill patients Br. J. Anaesth., April 1, 2005; 94(4): 459 - 467. [Abstract] [Full Text] [PDF]

				P. Tassani, H. Schad, C. Winkler, A. Bernhard, U. Ettner, S. L. Braun, G. P. Eising, E. Kochs, R. Lange, and J. A. Richter Capillary leak syndrome after cardiopulmonary bypass in elective, uncomplicated coronary artery bypass grafting operations: Does it exist? J. Thorac. Cardiovasc. Surg., April 1, 2002; 123(4): 735 - 741. [Abstract] [Full Text]